Report Phase 2b biopsy results for denifanstat in NASH

Delivered by the deadline

Under re-examination This entry has been challenged and is being re-checked against the sources.

What the company said

“Phase 2b fully-enrolled with biopsy results expected 1Q24”

SourceSagimet Biosciences Inc. Form 8-K press release, 2024-01-22
FilingSEC filing index
Deadline as stated1Q24
Deadline used31 Mar 2024, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2024-SGMT-000049
Cite as https://keptindex.org/c/KI-C-2024-SGMT-000049/ — this address never changes.

Sagimet announced positive topline Phase 2b biopsy results from FASCINATE-2 on January 22, 2024, within the stated Q1 2024 deadline.

A
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial Regulatory filing · published 6 Jun 2024 · retrieved 21 Sep 2026 · kept permanently by the SEC Subsequent detailed presentation of Phase 2b biopsy data at medical conference confirms results delivered
B
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH Company website · published 22 Jan 2024 · retrieved 21 Sep 2026 Company announcement of positive topline Phase 2b biopsy results on January 22, 2024

Checked 21 Sep 2026.

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Commitment recordedRecorded from the company's filing.
First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Sagimet Biosciences Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.